Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

Kirpichnikov, 2002, Metformin: an update, Ann Intern Med, 137, 25, 10.7326/0003-4819-137-1-200207020-00009

Scheen, 1996, Clinical pharmacokinetics of metformin, Clin Pharmacokinet, 30, 359, 10.2165/00003088-199630050-00003

Wright, 2005, Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics, Toxicol Appl Pharmacol, 204, 309, 10.1016/j.taap.2004.10.021

Leabman, 2002, Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function, Pharmacogenetics, 12, 395, 10.1097/00008571-200207000-00007

Yin, 2006, Variability in renal clearance of substrates for renal transporters in Chinese subjects, J Clin Pharmacol, 46, 157, 10.1177/0091270005283838

Leabman, 2003, Estimating the contribution of genes and environment to variation in renal drug clearance, Pharmacogenetics, 13, 581, 10.1097/00008571-200309000-00007

Hermann, 1994, Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study, Diabetes Care, 17, 1100, 10.2337/diacare.17.10.1100

Song, 2008, Genetic variants of the organic cation transporter 2 influence the disposition of metformin, Clin Pharmacol Ther, 84, 559, 10.1038/clpt.2008.61

Wang, 2007, OCT2 polymorphism and in vivo renal functional consequence: studies with metformin and cimetidine, Clin Pharmacol Ther, 81, 1

Chen, 2007, Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family, J Pharmacol Exp Ther, 322, 695, 10.1124/jpet.107.123554

Shu, 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics, Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275

Urban, 2008, Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin, Clin Pharmacol Ther, 83, 416, 10.1038/sj.clpt.6100271

Kang, 2007, Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population, Drug Metab Dispos, 35, 667, 10.1124/dmd.106.013581

Kimura, 2005, Metformin transport by renal basolateral organic cation transporter hOCT2, Pharm Res, 22, 255, 10.1007/s11095-004-1193-3

Sirtori, 1978, Disposition of metformin (N,N-dimethylbiguanide) in man, Clin Pharmacol Ther, 24, 683, 10.1002/cpt1978246683

Tucker, 1981, Metformin kinetics in healthy subjects and in patients with diabetes mellitus, Br J Clin Pharmacol, 12, 235, 10.1111/j.1365-2125.1981.tb01206.x

Sambol, 1995, Kidney function and age are both predictors of pharmacokinetics of metformin, J Clin Pharmacol, 35, 1094, 10.1002/j.1552-4604.1995.tb04033.x

Karim, 2007, Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug, J Clin Pharmacol, 47, 37, 10.1177/0091270006293755

Ogasawara, 2008, Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney, J Hum Genet, 53, 607, 10.1007/s10038-008-0288-9

Otsuka, 2005, A human transporter protein that mediates the final excretion step for toxic organic cations, Proc Natl Acad Sci U S A, 102, 17923, 10.1073/pnas.0506483102

Masuda, 2006, Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2, J Am Soc Nephrol, 17, 2127, 10.1681/ASN.2006030205

Tanihara, 2007, Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters, Biochem Pharmacol, 74, 359, 10.1016/j.bcp.2007.04.010